Future of HER2-Directed Tumor-Agnostic Therapies
Panelist discusses how HER2-directed tumor-agnostic treatments are likely to see expanded applications across multiple cancer types, driven by improved biomarker testing and emerging clinical evidence. This approach may become increasingly personalized through enhanced molecular profiling, potentially leading to more precise patient selection and combination strategies.
Video content above is prompted by the following:
- Where do you see the field of HER2-directed tumor-agnostic therapies evolving in the next 5 years?
Recent Videos
Related Content
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Georgios Evangelou, MD, MSc;Ioannis Vamvakaris, MD, PhD, MSc;Irene Konstantopoulou, PhD;Konstantinos Syrigos, PhD
July 10th 2024Article
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
